«

»

May 07

APR launches new Corporate Internet site.

The business repositioning is reflected in its revised logo design also. ‘The Pharmaceutical industry has always been driven by Development but today and much more in the potential we need new, more co-operative methods to approach innovation and this new paradigm can be valid for development businesses like APR,’ continuing Paolo Galfetti. Related StoriesApplying a high restaurant model to health care communications: an interview with Brandi Robinson, SanofiUsing integrated molecular pathology to control incidental pancreatic cysts: an interview with Dr Ananya DasReducing hospital readmissions through Transitional Care: an interview with Rani KhetarpalThe fresh APR Business Model is centered on Innovation and just how this is attracted, developed, recognized and managed: Attract Innovation: by opening to a wider selection of partnering opportunities including funding and direct investment in growing companies and tasks synergic with APR primary competencies; Develop Technology: the ability to strategy, manage and execute complex projects offering sustainable benefits to Healthcare providers and patients by merging together different models of know-how, resources and competence; Realizing Innovation: go beyond just licensing out the results of development, but also delivering solutions to customers, as provider contractor or through joint venture participations, and helping and enhancing the direct exploitation of the creativity; Managing Creativity: Capitalize on the partnerships to stay on the advantage of creativity for a long time period.All venograms and all episodes of suspected symptomatic venous thromboembolism, bleeding, myocardial infarction, stroke, thrombocytopenia, and death were adjudicated by an independent central adjudication committee whose members were unaware of the procedure assignments. Outcome Measures The primary efficacy outcome was the composite of adjudicated symptomatic or asymptomatic deep-vein thrombosis, non-fatal pulmonary embolism, or death from any cause through the intended treatment period . The principal safety outcome was bleeding during the treatment period or until 2 days following the last dosage of study medication was administered.